Back to Results
First PageMeta Content
Guanidines / Diabetes / Chemistry / Anti-diabetic medication / Nateglinide / Buformin / Metformin / Hypoglycemia / Astellas Pharma / Medicine / Endocrine system / Biguanides


November 14, 2007 SNDA FOR A FAST-ACTING POSTPRANDIAL HYPOGLICEMIC AGENT FASTIC® TABLET / STARSIS® TABLET FOR COMBINATION THERAPY WITH BIGUANIDE WAS APPROVED November 14, [removed]Tokyo - Ajinomoto Co., Inc. (Headquarter
Add to Reading List

Document Date: 2008-09-18 20:31:40

Open Document

File Size: 34,44 KB

Share Result on Facebook

City

Tokyo / Seoul / Basel / /

Company

Novartis Pharma AG / Ajinomoto Co. Inc. / Daiichi Sankyo Co. Ltd. / Ildong Pharmaceutical Co. Ltd. / Astellas Pharma Inc. Pharmaceutical / Astellas Pharma Inc. / /

Continent

Europe / /

Country

Switzerland / Japan / United States / South Korea / /

Event

FDA Phase / /

IndustryTerm

treatment of diabetes / /

MedicalCondition

insulin resistance / diabetes / non-insulin-dependent diabetes / /

Organization

Public Relations Office / /

Person

Norio Yamaguchi / Masafumi Nogimori / /

/

Position

President & CEO / /

Product

metformin hydrochloride / nateglinide / This agent / FASTIC® Tablet / /

Technology

alpha / /

SocialTag